摘要
目的:探讨布地奈德福莫特罗联合异丙托溴铵治疗慢性阻塞性肺疾病急性加重期(Acute Exacerbation of Chronic Obstructive Pulmonary Disease,AECOPD)的效果。方法:选取2021年1月至2024年6月期间本院收治的105例AECOPD患者作为研究对象,按照随机数字表法分为对照组(n=53)和观察组(n=52)。对照组接受异丙托溴铵治疗,观察组在对照组基础上采用布地奈德福莫特罗治疗。比较两组的症状消失时间、动脉血气指标[动脉血氧分压(Arterial partial pressure of oxygen,PaO_(2))、二氧化碳分压(Arterial partial pressure of carbon dioxide,PaCO_(2))]、呼吸困难程度[改良版英国医学研究委员会呼吸困难量表(Modified Medical Research Council,mMRC)]以及不良反应。结果:观察组喘息消失时间、咳嗽消失时间、肺啰音消失时间均明显短于对照组(P<0.05)。治疗后,两组PaO_(2)均明显高于治疗前,且观察组明显高于对照组(P<0.05);两组PaCO_(2)、mMRC评分均明显低于治疗前,且观察组明显低于对照组(P<0.05)。两组不良反应发生率无明显差异(P>0.05)。结论:布地奈德福莫特罗联合异丙托溴铵治疗,能提高临床疗效,改善AECOPD患者的血气指标,促进症状消失,且安全性较高。
Objective:To investigate the efficacy of budesonide formoterol combined with ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Method:A total of 105 AECOPD patients admitted to our hospital from January 2021 to June 2024 were selected as the study subjects and randomly divided into a control group(n=53)and an observation group(n=52)using a random number table method.The control group received treatment with ipratropium bromide,while the observation group received treatment with budesonide formoterol in addition to the control group.The disappearance time of symptoms,arterial blood gas indexes[Arterial partial pressure of oxygen(PaO_(2)),Arterial partial pressure of carbon dioxide(PaCO_(2))],degree of dyspnea[Modified Medical Research Council(mMRC)]and adverse reactions were analyzed and compared between the two groups.Result:The disappearance time of wheezing,cough,and lung rales in the observation group were significantly shorter than those in the control group(P<0.05).After treatment,the PaO_(2) levels in both groups were significantly higher than before treatment,and the observation group was significantly higher than the control group(P<0.05).The PaCO_(2) and mMRC scores of both groups were significantly lower than before treatment,and the observation group was significantly lower than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination therapy of budesonide formoterol and ipratropium bromide can improve clinical efficacy,improve blood gas indicators in AECOPD patients,promote symptom disappearance,and has high safety.
作者
王敬领
Wang Jing-ling(Department of Respiratory Medicine,Ningling People's Hospital,Ningling 476700,Henan,China)
关键词
慢阻肺急性加重期
布地奈德福莫特罗
异丙托溴铵
Acute exacerbation of chronic obstructive pulmonary disease
Budesonide formoterol
Ipratropium bromide.
作者简介
王敬领,男,副主任医师,主要从事呼吸内科临床工作,Email:3847016385@qq.com。
